FDA OKs breakthrough cholesterol drug for high-risk patients

FDA OKs breakthrough cholesterol drug for high-risk patients

WASHINGTON (AP) – The Food and Drug Administration says it has approved a breakthrough drug that lowers bad cholesterol more than older medicines that have been prescribed for decades.

The drug from Sanofi and Regeneron Pharmaceuticals Inc. offers an important new option for patients at high risk of heart disease. But experts have questions about the price and long-term benefits of the medication.

Praluent is the first in an experimental class of biotech medications that use a novel approach to lower bad, or LDL, cholesterol, which can lead to heart attack and stroke. The new drugs are considered the first major advance in the field since the introduction of statin drugs more than 20 years ago.

Analysts expect the new injectable drugs to generate billions in sales for Sanofi and other drug makers.

Copyright 2015 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s